March 1, 2023
FDA Grants First Marketing Rights for Anthrax Point-of-Care Test to InBios
By info@inbios.com|2023-08-16T17:55:13+00:00March 1st, 2023|InBios In the News|
FDA Grants First Marketing Rights for Anthrax Point-of-Care Test to InBios
By info@inbios.com|2022-11-22T19:52:40+00:00November 22nd, 2022|InBios In the News|
InBios Awarded Funding for Lyme Disease Diagnostic from HHS, Cohen Foundation
By info@inbios.com|2022-08-29T23:05:13+00:00August 29th, 2022|InBios In the News|
Rapid Antigen Tests Accurately Detect COVID Variants
By info@inbios.com|2022-08-29T23:02:33+00:00August 29th, 2022|InBios In the News|
Antigen Tests Accurately Detect COVID-19 Variants in Study
By info@inbios.com|2022-01-19T17:30:17+00:00January 19th, 2022|InBios In the News|
InBios Featured on NBC COVID-19 Update
By info@inbios.com|2022-01-03T21:52:28+00:00January 3rd, 2022|InBios In the News|
Manufacturers Rush to Ramp Up Rapid COVID Test Production
By info@inbios.com|2022-01-03T21:49:24+00:00January 3rd, 2022|InBios In the News|
Companies Produce 'Tens of Millions' More Rapid COVID Tests
By info@inbios.com|2022-01-03T21:33:44+00:00January 3rd, 2022|InBios In the News|
U.S. Testing Struggles to Keep Up with Omicron
By info@inbios.com|2022-01-03T20:05:56+00:00January 3rd, 2022|InBios In the News|
InBios Receives FDA EUA for Home Use Antigen Test for COVID-19
By info@inbios.com|2021-11-01T21:20:45+00:00November 1st, 2021|InBios In the News|
InBios Receives FDA EUA for COVID-19 Neutralizing Antibody ELISA